8:20 am Chair’s Opening Remarks
8:30 am Talk Reserved for Abzena
Optimizing Linker Stability Within Circulation to Eliminate Off-Target Toxicities
9:00 am Understanding the Role of Linker Stability in Accurate Payload Release to Guide Targeted Delivery of Your ADC
Synopsis
• Delving into how varying levels of hydrophobicity in the linker affects the stability
• Analyzing how and where the linker degrades
• Understanding which linker chemistry creates the most stable ADC
9:30 am Examining How to Maintain Linker Stability in High DAR ADCs
Synopsis
• Understanding how a higher DAR affects linker stability
• Examining how you can counter an increase in hydrophilicity as a result of a higher DAR
• Demonstration how the increase the hydrophobicity of the linker ensures the payloads remain conjugated
10:00 am Selecting the Correct Level of Stability to Ensure a Maximized Therapeutic Index for Your ADC
Synopsis
• Discussing how site of conjugation and drug linker modifications can reduce some offtarget toxicities with anti-mitotic ADCs
• Exploring how increased drug-linker stability can shift the dose-limiting toxicity of antimitotic ADCs away from bone marrow and towards more problematic toxicities
• Learning how the instability of the vedotin drug linker could be a key driver to its clinical success
10:30 am Morning Refreshments & Speed Networking
Synopsis
This session is an opportunity to connect with peers and hold in-depth conversations with some of the brightest minds in the ADC chemistry field to establish meaningful and lasting relationships.
Outlining Design Parameters to Increase Stability & Maximize Targeted Delivery
11:30 am Designing the Linker Efficiently to Ensure It Activates in the Correct Space
Synopsis
• Understanding how linker design affects activation
• Modulating the linker chemistry to make activation in the correct space possible
• Designing the linker to navigate tumor properties
12:00 pm A Reliable & Flexible Technology for the Rapid Conjugation of Antibodies & Other Biologics
Synopsis
• Discussing how Singzyme’s technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR
• Examining how this technology also allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market
12:30 pm Networking Lunch
1:00 pm Tumour-Selective Linker Chemistries
Synopsis
Talk Details TBC
1:30 pm Overcoming Chemical Diversity to Create a Focused Design Criteria for Your Linker
Synopsis
• Navigating the large chemical space of ADC linker
• Using the vast chemical space to design the most clinically relevant linker
• Focusing on what design criteria are the most important for your linker
Examining Novel Linkers to Expand Your Linker Chemistry Toolkit
2:00 pm Looking Beyond Cathepsins: Understanding & Optimizing Legumain- Cleavable ADC Linkers
Synopsis
• Overviewing the development of peptide libraries screened to identify new ADC linkers
• Demonstrating mechanism of legumain-cleavable linkers
• Learning functional and biophysical differentiation of legumain-cleavable linkers from cathepsin-cleavable linkers
2:30 pm Linker Matters: Highly Stable and Efficacious ADCs Made with Native Antibodies and Peptide Linkers
Synopsis
• Distinct biophysical properties and greatly enhanced stability
• Improved pharmacokinetics, efficacy and safety
• Resulting in ADCs show improved therapeutic indices vs FDA-approved ADCs
3:00 pm Afternoon Networking Break & Scientific Poster Session
Synopsis
- This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings.
4:00 pm Panel Discussion:Comparing Existing & Novel Linkers to Identify the Most Relevant Linkers to Take Into Your Early Drug Development
Synopsis
• Understanding if novel linkers are better than clinically active candidates
• Analyzing the difference in chemistry between novel linkers and existing ones
• Exploring how the development of novel linkers affects overall ADC